Trial · NCT06780865
Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension
NCT06780865, Not applicable, Not yet recruiting, Shanghai Institute of Hypertension
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension. Trials, record NCT06780865. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06780865
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension
- NCT number
- NCT06780865
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Shanghai Institute of Hypertension
- Conditions
- Chronic Kidney Disease(CKD), Nocturnal Hypertension
- Interventions
- Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine, Placebo-controlled group
- First posted
- 2025-01-17
- Last updated
- 2025-01-17
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in renal function from baseline after 2 year of treatment as assessed by EPI-estimated glomerular filtration rate (eGFR) | 2 years | |
| Secondary | Change in renal function from baseline after 1 year of treatment as assessed by EPI-estimated glomerular filtration rate (eGFR) | 1 year | |
| Secondary | Change in urine protein from baseline after 1 and 2 years of treatment as assessed by urinary albumin-to-creatinine ratio(UACR) | 1 and 2 years | |
| Secondary | 50% decrease of albumin-to-creatinine ratio (UACR) from baseline after 1 and 2 years of treatment | 1 and 2 years | |
| Secondary | Incidence of kidney composite endpoint including end-stage renal disease (ESRD), kidney replacement therapy, or sustained EPI-estimated glomerular filtration rate (eGFR) decline ≥ 40%. | 1 and 2 years | |
| Secondary | Incidence of sustained EPI-estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m² | 1 and 2 years | |
| Secondary | Incidence of cardiovascular endpoints including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or heart failure hospitalization | 1 and 2 years | |
| Secondary | Changes in cardiac injury after 1 and 2 years of treatment from baseline as assessed by left ventricular mass index or E/E' or cardiac troponin | 1 and 2 years | |
| Secondary | Changes in pulse wave velocity (PWV) after 1 and 2 years of treatment from baseline | 1 and 2 years | |
| Secondary | Incidence of mortality including all-cause, cardiovascular-related, and renal-related. | 1 and 2 years |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06780865
GET https://conductscience.org/api/trials/v1/NCT06780865/registered